SARS-CoV-2 ORF6 Antibody [CoraFluor™ 1]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-07037CL1
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
SARS-CoV-2
Applications
ELISA
Label
CoraFluor 1
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
This antibody was raised against a peptide corresponding to 15 amino acids near the Carboxyl terminus of SARS-CoV-2 (COVID-19) ORF6 protein. The immunogen is located in the last 50 amino acids of SARS-CoV-2 (COVID-19) ORF6.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
CoraFluor(TM) 1 is a high performance terbium-based TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) or TRF (Time-Resolved Fluorescence) donor for high throughput assay development. CoraFluor(IM) 1 absorbs UV light at approximately 340 nm, and emits at approximately 490 nm, 545 nm, 585 nm and 620 nm. It is compatible with common acceptor dyes that absorb at the emission wavelengths of CoraFluor(TM) 1. CoraFluor(TM) 1 can be used for the development of robust and scalable TR-FRET binding assays such as target engagement, ternary complex, protein-protein interaction and protein quantification assays.
Applications for SARS-CoV-2 ORF6 Antibody [CoraFluor™ 1]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Peptide affinity purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark. Do not freeze.
Background: SARS-CoV-2 ORF6
SARS-CoV-2 ORF6 is an ER/Golgi membrane protein that disrupts the formation of the nuclear import complex by binding karyopherin alpha 2 (KPNA2) and karyopherin beta 1 (KPNB1) (2, 4). More specifically, it was found that this disruption is mediated by ORF6's localization to the nuclear pore complex (NPC) where it binds Nup98-Rae1 to target the nuclear import pathway (5). This disruption further prevents the transport of signal transducer and activator of transcription 1 (STAT1) and ultimately blocks interferon (IFN) production and antiviral responses (2, 4, 5). It has been hypothesized that the pathology of COVID-19 is largely initiated by the SARS-CoV-2 proteins ORF6 and non-structural protein 1 (NSP1) which together inhibit STAT1 activity (4). The repression of STAT1 thereby instead promotes STAT3 activation and the upregulation of plasminogen activator inhibitor-1 (PAI-1), leading to a cascade of events that are key features of COVID-19 (4). These harmful events include thrombosis, production of cytokines and chemokines by macrophages, profibrotic changes, hypoxia, and eventual T-cell lymphopenia (4). These finding suggest that targeting STAT1 and STAT3 might be beneficial therapeutic strategies for treating COVID-19.
References
1. Michel, C. J., Mayenr, C., Poch, O., & Thompson, J. D. (2020). Characterization of accessory genes in coronavirus genomes. Virology journal. https://doi.org/10.1186/s12985-020-01402-1
2. UniProt (P0DTC6)
3. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The protein journal. https://doi.org/10.1007/s10930-020-09901-4
4. Matsuyama, T., Kubli, S. P., Yoshinaga, S. K., Pfeffer, K., & Mak, T. W. (2020). An aberrant STAT pathway is central to COVID-19. Cell death and differentiation, 1-17. Advance online publication. https://doi.org/10.1038/s41418-020-00633-7
5. Miorin, L., Kehrer, T., Sanchez-Aparicio, M. T., Zhang, K., Cohen, P., Patel, R. S., Cupic, A., Makio, T., Mei, M., Moreno, E., Danziger, O., White, K. M., Rathnasinghe, R., Uccellini, M., Gao, S., Aydillo, T., Mena, I., Yin, X., Martin-Sancho, L., Krogan, N. J., ... Garcia-Sastre, A. (2020). SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proceedings of the National Academy of Sciences of the United States of America, 202016650. Advance online publication. https://doi.org/10.1073/pnas.2016650117
Alternate Names
2019-nCoV ORF6, 2019-nCoV ORF6 Protein, Accessory Protein 6, COVID-19 Non-structural protein 6, COVID-19 ns6, COVID-19 ORF6, COVID-19 Protein X3, Human coronavirus ORF6 Protein, Non-structural protein 6, NS6, ORF6 protein, SARS-CoV-2, SARS-CoV-2 Accessory Protein 6, SARS-CoV-2 Non-structural protein 6, SARS-CoV-2 ns6, SARSCoV2 ORF6 Protein, SARS-CoV-2 ORF6 Protein, SARS-CoV-2 Protein X3, Severe Acute Respiratory Syndrome Coronavirus 2
Gene Symbol
ORF6
Additional SARS-CoV-2 ORF6 Products
Product Documents for SARS-CoV-2 ORF6 Antibody [CoraFluor™ 1]
Product Specific Notices for SARS-CoV-2 ORF6 Antibody [CoraFluor™ 1]
CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...